**Name of Journal:** *World Journal of Gastroenterology*

**Manuscript NO:** 57442

**Manuscript Type:** ORIGINAL ARTICLE

***Case Control Study***

**Short- and long-term outcomes associated with enhanced recovery after surgery protocol *vs* conventional management in patients undergoing laparoscopic gastrectomy**

Tian YL *et al*. Comparison between ERAS and CM results

Yu-Long Tian, Shou-Gen Cao, Xiao-Dong Liu, Ze-Qun Li, Gan Liu, Xing-Qi Zhang, Yu-Qi Sun, Xin Zhou, Dao-Sheng Wang, Yan-Bing Zhou

**Yu-Long Tian, Shou-Gen Cao, Xiao-Dong Liu, Ze-Qun Li, Gan Liu, Xing-Qi Zhang, Yu-Qi Sun, Xin Zhou, Dao-Sheng Wang, Yan-Bing Zhou,** Department of Gastrointestinal Surgery, Affiliated Hospital of Qingdao University, Qingdao 266003, Shandong Province, China

**Author contributions:** Zhou YZ and Tian YL conceived and designed the study; Tian YL, Cao SG, Liu XD, and Li ZQ drafted the manuscript; Sun YQ, Zhou X, and Wang DS completed data management and statistical analysis; all authors have agreed to be responsible for all aspects of the work.

**Corresponding author: Yan-Bing Zhou, MD, Professor,** Department of Gastrointestinal Surgery, Affiliated Hospital of Qingdao University, No. 16 Jiangsu Road, Shinan District, Qingdao 266003, Shandong Province, China. zhou\_yb2008@126.com

**Received:** June 9, 2020

**Revised:** August 2, 2020

**Accepted:** September 3, 2020

**Published online:** October 7, 2020

**Abstract**

BACKGROUND

At present, the enhanced recovery after surgery (ERAS) protocol is widely implemented in the field of gastric surgery. However, the effect of the ERAS protocol on the long-term prognosis of gastric cancer has not been reported.

AIM

To compare the effects of ERAS and conventional protocols on short-term outcomes and long-term prognosis after laparoscopic gastrectomy.

METHODS

We retrospectively analyzed the data of 1026 consecutive patients who underwent laparoscopic gastrectomy between 2012 and 2015. The patients were divided into either an ERAS group or a conventional group. The groups were matched in a 1:1 ratio using propensity scores based on covariates that affect cancer survival. The primary outcomes were the 5-year overall and cancer-specific survival rates. The secondary outcomes were the postoperative short-term outcomes and inflammatory indexes.

RESULTS

The patient demographics and baseline characteristics were similar between the two groups after matching. Compared to the conventional group, the ERAS group had a significantly shorter postoperative hospital day (7.09 d *vs* 8.67 d, *P* < 0.001), shorter time to first flatus, liquid intake, and ambulation (2.50 d *vs* 3.40 d, *P* < 0.001; 1.02 d *vs* 3.64 d, *P* < 0.001; 1.47 d *vs* 2.99 d, *P* < 0.001, respectively), and lower medical costs ($7621.75 *vs* $7814.16, *P* = 0.009). There was a significantly higher rate of postoperative complications among patients in the conventional group than among those in the ERAS group (18.1 *vs* 12.3, *P* = 0.030). Regarding inflammatory indexes, the C-reactive protein and procalcitonin levels on postoperative day 3/4 were significantly different between the two groups (*P* < 0.001 and *P* = 0.025, respectively). The ERAS protocol was associated with significantly improved 5-year overall survival and cancer-specific survival rates compared with conventional protocol (*P* = 0.013 and 0.032, respectively). When stratified by tumour stage, only the survival of patients with stage III disease was significantly different between the two groups (*P* = 0.044).

CONCLUSION

Adherence to the ERAS protocol improves both the short-term outcomes and the 5-year overall survival and cancer-specific survival of patients after laparoscopic gastrectomy.

**Key Words:** Enhanced recovery after surgery; Conventional management; Laparoscopic gastrectomy; Short-term outcomes; Survival

**Citation：** Tian YL, Cao SG, Liu XD, Li ZQ, Liu G, Zhang XQ, Sun YQ, Zhou X, Wang DS, Zhou YB. Short- and long-term outcomes associated with enhanced recovery after surgery protocol *vs* conventional management in patients undergoing laparoscopic gastrectomy. *World J Gastroenterol* 2020; 26(37): 5646-5660

**URL:** https://www.wjgnet.com/1007-9327/full/v26/i37/5646.htm

**DOI:** https://dx.doi.org/10.3748/wjg.v26.i37.5646

**Core Tip:** The results of this retrospective study suggest that enhanced recovery after surgery might be a promising perioperative management protocol for gastric cancer in terms of short-term and long-term outcomes. To the best of our knowledge, this is the first propensity score-matched study to reveal that the enhanced recovery after surgery protocol can improve the 5-year overall survival and cancer-specific survival rates of patients with gastric cancer.

**INTRODUCTION**

Globally, gastric cancer is a common malignant tumour and has the third highest mortality rate. In 2018, there were more than 1.3 million new cases of gastric cancer and more than 780000 gastric cancer related deaths[1]. The treatments and outcomes of gastric cancer have improved substantially over recent decades because of the introduction of new surgical techniques and chemotherapeutic drugs[2-5]. Enhanced recovery after surgery (ERAS) pathways have been proven to improve postoperative recovery and reduce postoperative complications, the length of hospital stay, and medical costs after gastric cancer surgery[6-8]. In a previously published randomized controlled trial, we investigated the relationship between postoperative compliance to ERAS protocols and short-term postoperative outcomes, and similar results were obtained[9]. Despite the short-term outcomes achieved with the perioperative ERAS protocol, the postoperative complication rate remains at approximately 10% to 30%.

Emerging evidence suggests that the ERAS protocol can influence long-term oncological outcomes after colorectal cancer surgery and elective orthopaedic surgery[10-12]. The mechanism behind this effect may not only be related to the reduction of complications and immune suppression but also to changes in immune response leading to a higher recurrence rate and distant metastasis rate[13-16]. However, it is not clear whether the ERAS regimen can improve the long-term prognosis of gastric cancer. Therefore, the aim of this retrospective study was to determine the effect of the ERAS protocol after laparoscopic gastrectomy on long-term survival. Moreover, short-term clinical outcomes and inflammatory parameters were compared between the ERAS and conventional protocols.

**MATERIALS AND METHODS**

***Study design and participants***

From January 2012 to December 2015, 1026 consecutive laparoscopic gastrectomies were performed at the Department of General Surgery of the Affiliated Hospital of Qingdao University, China. Data from these procedures were prospectively collected in a database and then retrospectively reviewed. The ERAS protocol was introduced in 2010 as a standard protocol for perioperative care in our department. Because the ERAS protocol was not be accepted by some patients at that time, based on the willingness of the patients, the department was divided into an ERAS ward (ERAS protocol) and a non-ERAS ward (conventional pathway). In the same period, we extensively performed laparoscopic surgery for gastric cancer. According to the postoperative pathological stage, patients with advanced gastric cancer were treated with S-1 combined with oxaliplatin for 6-8 cycles. All patients were followed by outpatient clinic visits and telephone interviews for up to 5 years after the primary operation.

After excluding some patients who did not meet the criteria, the ERAS group was matched in a ratio of 1:1 with the conventional group. Matching was achieved based on propensity scores including the following seven covariates: Age, American Society of Anesthesiology score, primary tumour location, histologic type, pathological stage, operation date, and adjuvant chemotherapy. The study design is shown in Figure 1.

***Perioperative management and operation***

Patients in the ERAS ward were managed according to the ERAS pathway during the perioperative period, the specific protocol includes 17 care elements (Table 1), and their compliance with all care elements was more than 80%, while the non-ERAS ward was managed according to the conventional pathway (Supplementary Table 1). To ensure recovery and reduce hospitalizations after gastric surgery, we paid particular attention to the ‘key components’ of the ERAS programme, namely, the following six basic elements: Preoperative patient information and education, thoracic epidural anaesthesia combined with multimodal analgesia, target-oriented liquid management, no nasogastric tube, early oral feeding, and early mobilization.

Before surgery, chest computed tomography (CT), abdominal enhanced CT, and pelvic CT were performed to confirm the size and location of the tumour, and distant organ metastases were excluded according to the evaluation by two experienced radiologists. Echocardiography and pulmonary function tests were used to evaluate the tolerance of cardiopulmonary function to laparoscopic surgery. Nutrition risk screening 2002 was used to evaluate the nutritional status of patients; if the score was ≥ 3, the patients were given nutritional support.

Laparoscopic-assisted radical resection of distal gastric cancer (D2 Billroth-I/Billroth-II/Roux-en-Y) was performed under general anaesthesia. During the operation, we followed the basic principles of tumour treatment, mastered the appropriate scope of gastrectomy, performed fine lymph node dissection and gastrointestinal reconstruction, and recorded the volume of intraoperative infusion, volume of blood loss, operation time, and use of opioids and muscle relaxants.

***Definition of surgical complications and mortality***

Complications and mortality were defined as those occurring within 30 d after gastrectomy. Intraoperative complications were defined as bleeding due to vessel injury, injury to visceral organs, mechanical factor-related problems, cardiopulmonary dysfunction due to hypercapnia, and other complications. Wound infection was defined as a skin and subcutaneous tissue infection. A specific complication was diagnosed on the basis of either a medical imaging examination or obvious clinical evidence. Gastroparesis referred to the occurrence of emptying difficulties after surgery, combined with clinical features and imaging examinations for a final diagnosis. Anastomotic complications such as leakage, stenosis, or intracavitary haemorrhage were confirmed by gastrointestinal X-ray imaging, endoscopy, or angiography. Intra-abdominal collections and abscesses were proven by ultrasonography or CT scans and had concomitant systemic inflammatory responses that lasted for at least 24 h. Both intraoperative major bleeding and postoperative haemorrhage were defined as an amount of haemorrhage exceeding 300 mL. Traumatic pancreatitis was defined as increased serum amylase levels exceeding three times the upper limit of normal accompanied by obvious clinical symptoms and signs. Lymphatic leakage was confirmed by a chyle test when the abdominal drainage fluid volume exceeded 300 mL per day for 5 continuous days after postoperative day (POD) 3. The severity of postoperative complications was assessed according to the Clavien-Dindo classification[17].

***Statistical analysis***

Categorical variables are described as numbers and percentages and were compared between groups using Pearson’s chi-square test or Fisher’s exact test. Continuous variables are described as the mean ± standard deviation. Non-normally distributed continuous data are presented as the median and interquartile range, and Student’s *t*-test was used for normally distributed continuous variables. Survival curves were plotted using the Kaplan-Meier method. The log-rank test was used to compare survival curves. Survival time was defined as the interval between the primary operation date and a new event or the last follow-up. Patients who did not experience any event and were still alive at 60 mo were censored at this time. Significance was defined as *P* < 0.05. All statistical tests were two-sided and performed using SPSS software version 24.0 (SPSS, Chicago, IL, United States).

***Ethical statement***

The study was approved by the Affiliated Hospital of Qingdao University Ethics Review Committee (No. QYFYKYLL-2018-34). All procedures were performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments.

**RESULTS**

***Compliance to the ERAS protocol***

Table 1 lists the specific ERAS programmes and compliance to its 17 care elements. The following three elements achieved 100% compliance: Health education, intraoperative safety check, and precision surgery scheme. As compliance to the ERAS programme is affected by multidisciplinary cooperation among surgeons, anaesthesiologists, and nurses as well as the physical status and willingness of patients, the compliance rate to partial elements is typically low. Fortunately, our ERAS team is united and cooperative, and the implementation rate of all elements was greater than 80%. According to the database, more than 90% of patients implemented four and more ‘key components’ of the ERAS protocol, which is essential for our research.

***Demographics and baseline characteristics***

After the ERAS group was matched in a 1:1 ratio to the conventional group, there were 365 patients in each group. The patient demographics and baseline characteristics are detailed in Table 2 (Pathologic stage according to the American Joint Committee on Cancer)[18]. The baseline characteristics were well balanced after matching. We can observe that with the advancement of surgical technology, the number of laparoscopic surgeries increased year by year. There were 245 and 233 patients in the ERAS group and the conventional group who received adjuvant chemotherapy, respectively.

***Surgical results***

In the matched population, the surgical results of the ERAS and conventional groups are presented in Table 3. The mean time to first flatus in the conventional group was 0.9 days longer than that in the ERAS group (3.40 d *vs* 2.50 d; *P* < 0.001). Both the time to first liquid intake (1.02 d *vs* 3.64 d; *P* < 0.001) and time to ambulation (1.47 d *vs* 2.99 d; *P* < 0.001) were earlier in the ERAS group than in the conventional group. Compared to the conventional group, the ERAS group had a significantly shorter postoperative hospital stay (7.09 d *vs* 8.67 d; *P* < 0.001) and lower medical costs ($7621.75 *vs* $7814.76; *P* = 0.009). There were no statistically significant differences between the two groups in the other surgical results, especially in 30-d reoperation and 30-d readmission.

***Postoperative complications***

Postoperative morbidity and mortality are reported in Table 4. Apart from a significantly higher rate of postoperative complications among patients in the conventional group than among those in the ERAS group (18.1 *vs* 12.3; *P* = 0.030), no significant differences in intraoperative complications, mortality, or Clavien-Dindo classification could be detected between the two groups. Moreover, according to the Clavien-Dindo classification of surgical complications, the distribution of severity (grade 3 or more) was similar between the two groups (*P =* 0.192). Remarkably, 20 (5.5%) patients in the ERAS group and 13 (3.6%) in the conventional group had pulmonary complications, with no statistically significant difference between the two groups (*P* = 0.212).

***Inflammatory indexes***

The serum white blood cell (WBC), C-reactive protein (CRP), and procalcitonin were used as indicators of the surgical stress response. On POD 1, the WBC, CRP, and procalcitonin levels increased significantly in both groups compared to the preoperative values (*P* < 0.05 for all). The WBC, CRP, and procalcitonin did not increase as much in the ERAS group as in the conventional group. In particular, the CRP (0.63 ± 0.33 *vs* 0.58 ± 0.30) and procalcitonin (90.61 ± 20.42 *vs* 78.35 ± 16.73) levels on POD 3/4 were significantly different between the two groups (*P* < 0.001, Figure 2A; *P* = 0.025, Figure 2B). There was no significant difference between the groups in terms of WBC (Figure 2C). Notably, from POD 4-6, all indicators of both groups gradually recovered.

***Survival***

The follow-up endpoint was December 31, 2019. The median follow-up duration was 67 (range, 3-92) mo. The deaths of 226 patients resulted in a 5-year overall survival (OS) rate of 72.9% (99 of 365) in the ERAS group and 65.2% (127 of 365) in the conventional group (log-rank test, *P* = 0.013, Figure 3A). ERAS interventions were associated with a significantly improved 5-year cancer-specific survival rate compared with that in the conventional group (*P* = 0.032, Figure 3B). When stratified by tumour stage, the 5-year OS rates were 91.8%, 83.3%, and 48.1% for stages I, II, and III disease in the ERAS group, respectively, but 90.2%, 76.7%, and 38.3% in the conventional group, respectively (Figure 3C). In particular, the 5-year OS rate of the ERAS group was better than that of the traditional group, but only the survival of patients with stage III disease was significantly different between the two groups (log-rank test, *P* = 0.044).

**DISCUSSION**

The results of this retrospective study suggest that ERAS might be a promising perioperative management protocol for gastric cancer in terms of short-term and long-term outcomes. To the best of our knowledge, this is the first propensity score-matched study to reveal that the ERAS protocol can improve the 5-year OS and cancer-specific survival rates of patients with gastric cancer.

In this study, the perioperative ERAS protocol for gastric cancer surgery included at least 17 independent components. The formulation of consensus guidelines for enhanced recovery after gastrectomy, which consisted of 25 items in 2014, filled in the gap of an ERAS protocol in the perioperative period of gastric cancer surgery[19]. After more than 10 years of development, the ERAS protocol has been further improved and developed; we also summarized the protocol. Many studies have shown that compliance to the ERAS protocol is closely related to the surgical outcome[20,21]. In fact, fully implementing the ERAS protocol in clinical practice is indeed a challenge, and a nationwide survey in Korea also found similar problems[22]. There are many reasons behind these challenges, and they include a lack of knowledge, lack of acceptance, lack of ability, or lack of wish to change, or lack of clinical leadership; thus, many elements have to be implemented in a busy clinical department[23]. Fortunately, with total multidisciplinary collaboration among anaesthesiologists, surgeons, nurses, and physiotherapists, the patients' adherence to all components was greater than 80%. Research from the ERAS Compliance Group showed that increasing the compliance to an ERAS programme independently improved outcomes[24]. Next, we will pay more attention to focusing on how to improve patient compliance, including strengthening ERAS care training, strengthening education, improving clinical leadership, and simplifying the ERAS elements.

ERAS protocols in elective radical gastrectomy for gastric cancer have been widely accepted, and the evidence behind the feasibility and safety of ERAS has repeatedly been shown[20,21]. After the ERAS group was matched with the conventional group, there were no differences in demographics or baseline characteristics between the two groups in this study. The present study showed that ERAS is a safe and feasible protocol for gastric cancer because this approach led to a faster recovery, shorter hospital stay, and lower medical costs. Moreover, the total incidence of postoperative complications in the ERAS group was significantly lower than that in the conventional group. Although there was no significant difference, the incidence of pulmonary complications and wound infections in the ERAS group was lower than that in the conventional group, which may be related to the use of pre-rehabilitation (health education, exercise advice, psychological guidance, organ function evaluation and intervention, and nutritional assessment and intervention), multimodal analgesia, and early mobilization and intake. In addition, it is worth mentioning that the 30-d reoperation and readmission and perioperative mortality rates were not different between the two groups.

Surgical trauma will stimulate the release of a large number of inflammatory molecules, such as CRP, procalcitonin, interleukin-6 (IL-6), and necrosis factor-alpha (TNF-α), which will lead to a systemic inflammatory response, affect immune function, and increase the incidence of postoperative symptoms. CRP is one of the most commonly used inflammatory proteins to study acute response, and its expression level is related to the stress response to surgery. In healthy people, procalcitonin levels are very low, but lipopolysaccharides, microbial toxins, and inflammatory mediators (IL-6 or TNF-α) can directly or indirectly cause its increase during inflammation. Therefore, procalcitonin also reflects systemic inflammatory response and stress activity. Although the CRP and procalcitonin levels on POD 3/4 were significantly different between the two groups, the WBC, CRP, and procalcitonin did not increase as much in the ERAS group as in the conventional group. The results of this study are similar to those of previous studies: The ERAS pathway can reduce the postoperative stress response[20].

The adoption of ERAS principles is increasing due to the significantly better short-term outcomes, but little is known about how ERAS can improve long-term prognosis. All things considered, the results of this study seem to have established that ERAS is superior to the conventional protocol in terms of oncological outcomes, particularly for stage III gastric cancer. Although there was no significant difference in survival of patients with stage II disease, the 5-year OS rate in the ERAS group was better than that in the conventional group. We conducted a retrospective study of gastric cancer patients who underwent standard radical gastrectomy from 2007 to 2012 and reached similar conclusions[25]. However, there are several potential explanations for why compliance to ERAS protocols better contributed to improved survival. First, perioperative complications have been shown to be strongly associated with impaired long-term outcomes[26,27]. This could be the result of either delayed adjuvant chemoradiation or no adjuvant chemoradiation in complicated cases[28]. Moreover, ERAS protocols can bring potential benefits to advanced gastric cancer that may be related to a lower stress response and reduction in insulin resistance, which are considered to be factors associated with a good cancer long-term prognosis[29-31]. Studies show that a relative perioperative cortisol deficiency appears to be an under-recognised contributor to perioperative organ injury[32]. Recent data from high-dose preoperative steroid administrations (*i.e.*, greater than 8 mg dexamethasone) are promising and showed that this approach improves pain relief, reduces the inflammatory response and early fatigue, and enhances patient recovery[33]. Furthermore, environmental challenges that affect the patient perioperatively, such as psychological distress, intraoperative hypothermia, and use of anaesthetic drugs or blood transfusions, also trigger a variety of stress responses that can substantially affect the metastatic process through effects on distal malignant cells, their microenvironment, and interacting immunocytes[34-36]. In contrast, ERAS protocols advocate for preoperative education, pre-rehabilitation, an avoidance of intraoperative hypothermia, multimodal analgesia, and an avoidance of unnecessary blood transfusions to reduce the stress response of surgical patients[37]. The unavoidable damage to the patients’ tissues and the removal and manipulations of the primary tumour during surgery have been shown to increase tumour cell shedding into the blood and lymphatic systems and to decrease systemic levels of primary tumour-associated antiangiogenic factors (such as endostatin)[38,39]. In addition, the patients’ paracrine and neuroendocrine responses to surgery, including the release of prostaglandins and catecholamines, facilitate malignant cell survival, motility, invasion, and proliferation and the release of proangiogenic factors, and suppress antimetastatic immunity[40,41]. In summary, every element plays an important role in the ERAS protocol, and even a combination of small changes can have a large impact on the outcome.

Our study has several limitations. First, we attempted to analyse the changes in stress response, but due to the limitations of retrospective data, there was no analysis of additional indicators (TNF-α and IL-6). Second, many components related to the time-varying ERAS protocol may have affected the results regarding both short-term and long-term outcomes; however, the weight of these components in the ERAS protocol requires further evaluation to determine the rational essential elements. Third, it is impossible to clarify the mechanism behind the influence of the ERAS protocol on short-term and long-term outcomes; detailed mechanistic studies are needed in the future. Finally, this was a single-centre retrospective study; therefore, multicentre randomised controlled trial studies should be performed to verify the reliability of the results. Fortunately, we have registered (Chinese Clinical Trial Registry, CHiCTR1900022438) and started such a project, and patients are currently being recruited[42]. We hope that our data will provide trustworthy evidence that the ERAS pathway improves survival in patients with gastric cancer.

**CONCLUSION**

In conclusion, the ERAS protocol has been proven to be a safe and effective perioperative management pathway in the current literature. In particular, the ERAS protocol has shown promising results in improving the survival of patients with gastric cancer after surgery.

**ARTICLE HIGHLIGHTS**

***Research background***

At present, the enhanced recovery after surgery (ERAS) protocol is widely implemented in the field of gastric surgery. Emerging evidence suggests that the ERAS protocol can influence long-term oncological outcomes after colorectal cancer surgery and elective orthopaedic surgery. However, the effect of the ERAS protocol on the long-term prognosis of gastric cancer has not been reported.

***Research motivation***

We urgently need to understand that ERAS can improve the long-term prognosis of patients with gastric cancer, so as to standardize our clinical care and improve the terms of ERAS protocol.

***Research objectives***

The primary aim of this retrospective study was to determine the effect of the ERAS protocol after laparoscopic gastrectomy on long-term survival. The secondary aim was to compare short-term clinical outcomes and inflammatory parameters between the ERAS and conventional protocols.

***Research methods***

We retrospectively analyzed the data of 1026 consecutive patients who underwent laparoscopic gastrectomy between 2012 and 2015. Data from these procedures were prospectively collected in a database and then retrospectively reviewed. The patients were divided into either an ERAS group or a conventional group based on the willingness of the patients. The groups were matched in a 1:1 ratio using propensity scores based on covariates that affect cancer survival. The primary outcomes were the 5-year overall and cancer-specific survival rates. The secondary outcomes were the postoperative short-term outcomes and inflammatory indexes.

***Research results***

The patient demographics and baseline characteristics were similar between the two groups after matching. Compared to the conventional group, the ERAS group had a significantly shorter postoperative hospital day (7.09 d *vs* 8.67 d, *P* < 0.001), shorter time to first flatus, liquid intake, and ambulation (2.50 d *vs* 3.40 d, *P* < 0.001; 1.02 d *vs* 3.64 d, *P* < 0.001; 1.47 d *vs* 2.99 d, *P* < 0.001, respectively), and lower medical costs ($7621.75 *vs* $7814.16, *P* = 0.009). There was a significantly higher rate of postoperative complications among patients in the conventional group than among those in the ERAS group (18.1 *vs* 12.3, *P* = 0.030). Regarding inflammatory indexes, the C-reactive protein and procalcitonin levels on postoperative day 3/4 were significantly different between the two groups (*P* < 0.001 and *P* = 0.025, respectively). The ERAS protocol was associated with significantly improved 5-year overall survival and cancer-specific survival rates compared with conventional protocol (*P* = 0.013, *P* = 0.032, respectively). When stratified by tumour stage, only the survival of patients with stage III disease was significantly different between groups (*P* = 0.044).

***Research conclusions***

The ERAS protocol has been proven to be a safe and effective perioperative management pathway in the current literature. In particular, the ERAS protocol has shown promising results in improving the survival of patients with gastric cancer after surgery.

***Research perspectives***

This was a single-centre retrospective study; therefore, multicentre randomised controlled trial studies should be performed to verify the reliability of the results. Fortunately, we have registered (Chinese Clinical Trial Registry, CHiCTR1900022438) and started such a project, and patients are currently being recruited. We hope that our data will provide trustworthy evidence that the ERAS pathway improves survival in patients with gastric cancer.

**ACKNOWLEDGEMENTS**

We thank the patients participating in the study as well as the nurses and the management staff at the hospital. We also thank Wang H and Wang LK for contribution to the data collection.

**REFERENCES**

1 **Bray F**, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA Cancer J Clin* 2018; **68**: 394-424 [PMID: 30207593 DOI: 10.3322/caac.21492]

2 **Yu J**, Huang C, Sun Y, Su X, Cao H, Hu J, Wang K, Suo J, Tao K, He X, Wei H, Ying M, Hu W, Du X, Hu Y, Liu H, Zheng C, Li P, Xie J, Liu F, Li Z, Zhao G, Yang K, Liu C, Li H, Chen P, Ji J, Li G; Chinese Laparoscopic Gastrointestinal Surgery Study (CLASS) Group. Effect of Laparoscopic *vs* Open Distal Gastrectomy on 3-Year Disease-Free Survival in Patients With Locally Advanced Gastric Cancer: The CLASS-01 Randomized Clinical Trial. *JAMA* 2019; **321**: 1983-1992 [PMID: 31135850 DOI: 10.1001/jama.2019.5359]

3 **Lee HJ**, Hyung WJ, Yang HK, Han SU, Park YK, An JY, Kim W, Kim HI, Kim HH, Ryu SW, Hur H, Kong SH, Cho GS, Kim JJ, Park DJ, Ryu KW, Kim YW, Kim JW, Lee JH, Kim MC; Korean Laparo-endoscopic Gastrointestinal Surgery Study (KLASS) Group. Short-term Outcomes of a Multicenter Randomized Controlled Trial Comparing Laparoscopic Distal Gastrectomy With D2 Lymphadenectomy to Open Distal Gastrectomy for Locally Advanced Gastric Cancer (KLASS-02-RCT). *Ann Surg* 2019; **270**: 983-991 [PMID: 30829698 DOI: 10.1097/SLA.0000000000003217]

4 **Bang YJ**, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, Lordick F, Ohtsu A, Omuro Y, Satoh T, Aprile G, Kulikov E, Hill J, Lehle M, Rüschoff J, Kang YK; ToGA Trial Investigators. Trastuzumab in combination with chemotherapy *vs* chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. *Lancet* 2010; **376**: 687-697 [PMID: 20728210 DOI: 10.1016/S0140-6736(10)61121-X]

5 **Sasako M**, Sano T, Yamamoto S, Kurokawa Y, Nashimoto A, Kurita A, Hiratsuka M, Tsujinaka T, Kinoshita T, Arai K, Yamamura Y, Okajima K; Japan Clinical Oncology Group. D2 Lymphadenectomy alone or with para-aortic nodal dissection for gastric cancer. *N Engl J Med* 2008; **359**: 453-462 [PMID: 18669424 DOI: 10.1056/NEJMoa0707035]

6 **Yamada T**, Hayashi T, Cho H, Yoshikawa T, Taniguchi H, Fukushima R, Tsuburaya A. Usefulness of enhanced recovery after surgery protocol as compared with conventional perioperative care in gastric surgery. *Gastric Cancer* 2012; **15**: 34-41 [PMID: 21573918 DOI: 10.1007/s10120-011-0057-x]

7 **Sugisawa N**, Tokunaga M, Makuuchi R, Miki Y, Tanizawa Y, Bando E, Kawamura T, Terashima M. A phase II study of an enhanced recovery after surgery protocol in gastric cancer surgery. *Gastric Cancer* 2016; **19**: 961-967 [PMID: 26260875 DOI: 10.1007/s10120-015-0528-6]

8 **Tanaka R**, Lee SW, Kawai M, Tashiro K, Kawashima S, Kagota S, Honda K, Uchiyama K. Protocol for enhanced recovery after surgery improves short-term outcomes for patients with gastric cancer: a randomized clinical trial. *Gastric Cancer* 2017; **20**: 861-871 [PMID: 28062937 DOI: 10.1007/s10120-016-0686-1]

9 **Wang D**, Kong Y, Zhong B, Zhou X, Zhou Y. Fast-track surgery improves postoperative recovery in patients with gastric cancer: a randomized comparison with conventional postoperative care. *J Gastrointest Surg* 2010; **14**: 620-627 [PMID: 20108171 DOI: 10.1007/s11605-009-1139-5]

10 **Gustafsson UO**, Oppelstrup H, Thorell A, Nygren J, Ljungqvist O. Adherence to the ERAS protocol is Associated with 5-Year Survival After Colorectal Cancer Surgery: A Retrospective Cohort Study. *World J Surg* 2016; **40**: 1741-1747 [PMID: 26913728 DOI: 10.1007/s00268-016-3460-y]

11 **Savaridas T**, Serrano-Pedraza I, Khan SK, Martin K, Malviya A, Reed MR. Reduced medium-term mortality following primary total hip and knee arthroplasty with an enhanced recovery program. A study of 4,500 consecutive procedures. *Acta Orthop* 2013; **84**: 40-43 [PMID: 23368747 DOI: 10.3109/17453674.2013.771298]

12 **Pisarska M**, Torbicz G, Gajewska N, Rubinkiewicz M, Wierdak M, Major P, BudzyÅ„ski A, Ljungqvist O, PÄ™dziwiatr M. Compliance with the ERAS Protocol and 3-Year Survival After Laparoscopic Surgery for Non-metastatic Colorectal Cancer. *World J Surg* 2019; **43**: 2552-2560 [PMID: 31286185 DOI: 10.1007/s00268-019-05073-0]

13 **Smith T**, Li X, Nylander W, Gunnar W. Thirty-Day Postoperative Mortality Risk Estimates and 1-Year Survival in Veterans Health Administration Surgery Patients. *JAMA Surg* 2016; **151**: 417-422 [PMID: 26747331 DOI: 10.1001/jamasurg.2015.4882]

14 **Holmgren L**, O'Reilly MS, Folkman J. Dormancy of micrometastases: balanced proliferation and apoptosis in the presence of angiogenesis suppression. *Nat Med* 1995; **1**: 149-153 [PMID: 7585012 DOI: 10.1038/nm0295-149]

15 **Oosterling SJ**, van der Bij GJ, Meijer GA, Tuk CW, van Garderen E, van Rooijen N, Meijer S, van der Sijp JR, Beelen RH, van Egmond M. Macrophages direct tumour histology and clinical outcome in a colon cancer model. *J Pathol* 2005; **207**: 147-155 [PMID: 16104052 DOI: 10.1002/path.1830]

16 **Mantovani A**, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. *Nature* 2008; **454**: 436-444 [PMID: 18650914 DOI: 10.1038/nature07205]

17 **Dindo D**, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. *Ann Surg* 2004; **240**: 205-213 [PMID: 15273542 DOI: 10.1097/01.sla.0000133083.54934.ae]

18 **Edge SB,** Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A, editors. American Joint Committee on Cancer AJCC Cancer Staging Manual. 7th ed[M]. New York, NY: Springer, 2010

19 **Mortensen K**, Nilsson M, Slim K, Schäfer M, Mariette C, Braga M, Carli F, Demartines N, Griffin SM, Lassen K; Enhanced Recovery After Surgery (ERAS®) Group. Consensus guidelines for enhanced recovery after gastrectomy: Enhanced Recovery After Surgery (ERAS®) Society recommendations. *Br J Surg* 2014; **101**: 1209-1229 [PMID: 25047143 DOI: 10.1002/bjs.9582]

20 **Wee IJY**, Syn NL, Shabbir A, Kim G, So JBY. Enhanced recovery *vs* conventional care in gastric cancer surgery: a meta-analysis of randomized and non-randomized controlled trials. *Gastric Cancer* 2019; **22**: 423-434 [PMID: 30805742 DOI: 10.1007/s10120-019-00937-9]

21 **So JB**, Lim ZL, Lin HA, Ti TK. Reduction of hospital stay and cost after the implementation of a clinical pathway for radical gastrectomy for gastric cancer. *Gastric Cancer* 2008; **11**: 81-85 [PMID: 18595014 DOI: 10.1007/s10120-008-0458-7]

22 **Jeong O**, Kim HG. Implementation of Enhanced Recovery after Surgery (ERAS) Program in Perioperative Management of Gastric Cancer Surgery: a Nationwide Survey in Korea. *J Gastric Cancer* 2019; **19**: 72-82 [PMID: 30944760 DOI: 10.5230/jgc.2019.19.e3]

23 **Kehlet H**. ERAS Implementation-Time To Move Forward. *Ann Surg* 2018; **267**: 998-999 [PMID: 29462010 DOI: 10.1097/SLA.0000000000002720]

24 **ERAS Compliance Group**. The Impact of Enhanced Recovery Protocol Compliance on Elective Colorectal Cancer Resection: Results From an International Registry. *Ann Surg* 2015; **261**: 1153-1159 [PMID: 25671587 DOI: 10.1097/SLA.0000000000001029]

25 **Yang FZ**, Wang H, Wang DS, Niu ZJ, Li SK, Zhang J, Lü L, Chen D, Li Y, Jiang HT, Han HD, Chu HC, Cao SG, Zhou YB. [The effect of perioperative ERAS pathway management on short-and long-term outcomes of gastric cancer patients]. *Zhonghua Yi Xue Za Zhi* 2020; **100**: 922-927 [PMID: 32234167 DOI: 10.3760/cma.j.cn112137-20190711-01325]

26 **Khuri SF**, Henderson WG, DePalma RG, Mosca C, Healey NA, Kumbhani DJ; Participants in the VA National Surgical Quality Improvement Program. Determinants of long-term survival after major surgery and the adverse effect of postoperative complications. *Ann Surg* 2005; **242**: 326-41; discussion 341-3 [PMID: 16135919 DOI: 10.1097/01.sla.0000179621.33268.83]

27 **Wang S**, Xu L, Wang Q, Li J, Bai B, Li Z, Wu X, Yu P, Li X, Yin J. Postoperative complications and prognosis after radical gastrectomy for gastric cancer: a systematic review and meta-analysis of observational studies. *World J Surg Oncol* 2019; **17**: 52 [PMID: 30885211 DOI: 10.1186/s12957-019-1593-9]

28 **Kanda M**, Ito S, Mochizuki Y, Teramoto H, Ishigure K, Murai T, Asada T, Ishiyama A, Matsushita H, Tanaka C, Kobayashi D, Fujiwara M, Murotani K, Kodera Y. Multi-institutional analysis of the prognostic significance of postoperative complications after curative resection for gastric cancer. *Cancer Med* 2019; **8**: 5194-5201 [PMID: 31353821 DOI: 10.1002/cam4.2439]

29 **Palumbo JS**, Talmage KE, Massari JV, La Jeunesse CM, Flick MJ, Kombrinck KW, Jirousková M, Degen JL. Platelets and fibrin(ogen) increase metastatic potential by impeding natural killer cell-mediated elimination of tumor cells. *Blood* 2005; **105**: 178-185 [PMID: 15367435 DOI: 10.1182/blood-2004-06-2272]

30 **Hiller JG**, Perry NJ, Poulogiannis G, Riedel B, Sloan EK. Perioperative events influence cancer recurrence risk after surgery. *Nat Rev Clin Oncol* 2018; **15**: 205-218 [PMID: 29283170 DOI: 10.1038/nrclinonc.2017.194]

31 **van der Bij GJ**, Oosterling SJ, Beelen RH, Meijer S, Coffey JC, van Egmond M. The perioperative period is an underutilized window of therapeutic opportunity in patients with colorectal cancer. *Ann Surg* 2009; **249**: 727-734 [PMID: 19387333 DOI: 10.1097/SLA.0b013e3181a3ddbd]

32 **Manou-Stathopoulou V**, Korbonits M, Ackland GL. Redefining the perioperative stress response: a narrative review. *Br J Anaesth* 2019; **123**: 570-583 [PMID: 31547969 DOI: 10.1016/j.bja.2019.08.011]

33 **de la Motte L**, Kehlet H, Vogt K, Nielsen CH, Groenvall JB, Nielsen HB, Andersen A, Schroeder TV, Lönn L. Preoperative methylprednisolone enhances recovery after endovascular aortic repair: a randomized, double-blind, placebo-controlled clinical trial. *Ann Surg* 2014; **260**: 540-8; discussion 548-9 [PMID: 25115430 DOI: 10.1097/SLA.0000000000000895]

34 **Hijazi Y**, Gondal U, Aziz O. A systematic review of prehabilitation programs in abdominal cancer surgery. *Int J Surg* 2017; **39**: 156-162 [PMID: 28161527 DOI: 10.1016/j.ijsu.2017.01.111]

35 **Squires MH 3rd**, Kooby DA, Poultsides GA, Weber SM, Bloomston M, Fields RC, Pawlik TM, Votanopoulos KI, Schmidt CR, Ejaz A, Acher AW, Worhunsky DJ, Saunders N, Levine EA, Jin LX, Cho CS, Winslow ER, Russell MC, Staley CA, Maithel SK. Effect of Perioperative Transfusion on Recurrence and Survival after Gastric Cancer Resection: A 7-Institution Analysis of 765 Patients from the US Gastric Cancer Collaborative. *J Am Coll Surg* 2015; **221**: 767-777 [PMID: 26228017 DOI: 10.1016/j.jamcollsurg.2015.06.012]

36 **Horowitz M**, Neeman E, Sharon E, Ben-Eliyahu S. Exploiting the critical perioperative period to improve long-term cancer outcomes. *Nat Rev Clin Oncol* 2015; **12**: 213-226 [PMID: 25601442 DOI: 10.1038/nrclinonc.2014.224]

37 **Kehlet H**, Wilmore DW. Evidence-based surgical care and the evolution of fast-track surgery. *Ann Surg* 2008; **248**: 189-198 [PMID: 18650627 DOI: 10.1097/SLA.0b013e31817f2c1a]

38 **Yamaguchi K**, Takagi Y, Aoki S, Futamura M, Saji S. Significant detection of circulating cancer cells in the blood by reverse transcriptase-polymerase chain reaction during colorectal cancer resection. *Ann Surg* 2000; **232**: 58-65 [PMID: 10862196 DOI: 10.1097/00000658-200007000-00009]

39 **O'Reilly MS**, Boehm T, Shing Y, Fukai N, Vasios G, Lane WS, Flynn E, Birkhead JR, Olsen BR, Folkman J. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. *Cell* 1997; **88**: 277-285 [PMID: 9008168 DOI: 10.1016/s0092-8674(00)81848-6]

40 **Thaker PH**, Sood AK. Neuroendocrine influences on cancer biology. *Semin Cancer Biol* 2008; **18**: 164-170 [PMID: 18201896 DOI: 10.1016/j.semcancer.2007.12.005]

41 **Gullino PM**. Prostaglandins and gangliosides of tumor microenvironment: their role in angiogenesis. *Acta Oncol* 1995; **34**: 439-441 [PMID: 7540024 DOI: 10.3109/02841869509094005]

42 **Tian Y**, Cao S, Li L, He Q, Xia L, Jiang L, Ding Y, Wang X, Wang H, Mao W, Hui X, Shi Y, Zhang H, Chu X, Kehlet H, Zhou Y. Effects of perioperative enhanced recovery after surgery pathway management *vs* traditional management on the clinical outcomes of laparoscopic-assisted radical resection of distal gastric cancer: study protocol for a randomized controlled trial. *Trials* 2020; **21**: 369 [PMID: 32357913 DOI: 10.1186/s13063-020-04272-8]

**Footnotes**

**Institutional review board statement:** The study was reviewed and approved by the Affiliated Hospital of Qingdao University Ethics Review Committee.

**Informed consent statement:** All study participants, or their legal guardian, provided informed written consent prior to study enrollment.

**Conflict-of-interest statement:** The authors have no conflicts of interest to declare.

**Data sharing statement:** No additional data are available.

**STROBE statement:** The authors have read the STROBE Statement—checklist of items, and the manuscript was prepared and revised according to the STROBE Statement—checklist of items.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/

**Manuscript source:** Unsolicited manuscript

**Peer-review started:** June 9, 2020

**First decision:** July 25, 2020

**Article in press:** September 3, 2020

**Specialty type:** Gastroenterology and hepatology

**Country/Territory of origin:** China

**Peer-review report’s scientific quality classification**

Grade A (Excellent): A

Grade B (Very good): B

Grade C (Good): 0

Grade D (Fair): 0

Grade E (Poor): 0

**P-Reviewer:** Yeoh SW **S-Editor:** Gao CC **L-Editor:** Wang TQ **P-Editor:**

Ma YJ

**Figure Legends**



**Figure 1 Flow diagram of patient selection process.** GC: Gastric cancer; ASA: American Society of Anesthesiologists; ERAS: Enhanced recovery after surgery.



**Figure 2 Comparison of levels of inflammatory indexes in the two groups.** A: C-reactive protein; B: Procalcitonin; C: White blood cell count. POD: Postoperative day; ERAS: Enhanced recovery after surgery.





**Figure 3 Kaplan-Meier curves.** A: 5-yr overall survival; B: 5-yr cancer-specific survival; C: 5-yr overall survival for stages I, II, and III disease between the two groups.ERAS: Enhanced recovery after surgery.

**Table 1 Compliance with the enhanced recovery after surgery protocol in enhanced recovery after surgery group**

|  |  |
| --- | --- |
| **ERAS variable** | **Compliance (%) *n* = 365** |
| Health education, exercise advice, dietary guidance | 365 (100) |
| Organ function evaluation, pre-rehabilitation treatment | 312 (85.5) |
| Fasting for 6 h and drinking for 2 h before operation | 332 (91.0) |
| No indwelling nasogastric tube | 310 (84.9) |
| Intraoperative safety check (WHO check list) | 365 (100) |
| Precision surgery scheme | 365 (100) |
| Goal-directed therapy | 306 (83.8) |
| Epidural anesthesia/analgesia | 299 (81.9) |
| Intraoperative heat preservation | 349 (95.6) |
| Small midline (< 8 cm) incision of upper abdomen | 358 (98.1) |
| Incision infiltration anesthesia | 310 (93.2) |
| Multimodal analgesia | 358 (98.1) |
| Prevention of deep venous thrombosis | 348 (95.3) |
| Mobilization on the first postoperative day | 320 (87.7) |
| Oral diet on the first postoperative day | 311 (85.2) |
| Early removal of catheter (< 24 h) | 339 (92.9) |
| Early extraction of abdominal drainage tube (< 48 h) | 304 (83.3) |

ERAS: Enhanced recovery after surgery; WHO: World Health Organization.

**Table 2 Patient demographics and baseline characteristics**

|  |  |  |
| --- | --- | --- |
|  | **Entire cohort** | **Propensity score matched cohort** |
|  | **Conventional group (*n* = 433)** | **ERAS group (*n* = 394)** | ***P* value** | **Conventional group (*n* = 365)** | **ERAS group (*n* =365)** | ***P* value** |
| Age, yr (mean ± SD) | 59.4 ± 10.2 | 59.6 ± 10.3 | 0.105 | 59.4 ± 10.3 | 59.5 ± 10.3 | 0.881 |
| Gender | 　 | 　 | 0.534 | 　 | 　 | 0.810 |
| Male, *n* (%) | 298 (68.8) | 279 (70.8) |  | 253 (69.3) | 256 (70.1) |  |
| Female, *n* (%) | 135 (31.2) | 115 (29.2) |  | 112 (30.7) | 109 (29.9) |  |
| BMI, kg/m2 (mean ± SD) | 23.7 ± 3.0 | 24.0 ± 3.1 | 0.287 | 23.8 ± 3.2 | 24.0 ± 3.1 | 0.379 |
| ASA score | 　 | 　 | 0.594 | 　 | 　 | 0.833 |
| I, *n* (%) | 226 (52.2) | 210 (53.3) |  | 190 (52.1) | 196 (53.7) |  |
| II, *n* (%) | 179 (41.3) | 165 (41.9) |  | 153 (41.9) | 152 (41.6) |  |
| III, *n* (%) | 28 (6.5) | 19 (4.9) |  | 22 (6.0) | 17 (4.7) |  |
| NRS 2002 |  |  | 0.784 |  |  | 0.767 |
| < 3 | 197 (45.5) | 183 (46.4) |  | 165 (45.2) | 169 (46.3) |  |
| ≥ 3 | 236 (54.5) | 211 (53.6) |  | 200 (54.8) | 196 (53.7) |  |
| Comorbidity | 　 | 　 | 　 | 　 | 　 | 　 |
| Diabetes, *n* (%) | 52 (12.0) | 36 (9.1) | 0.181 | 35 (9.6) | 32 (8.8) | 0.700 |
| Cardiovascular, *n* (%) | 80 (18.5) | 52 (13.2) | 0.038 | 49 (13.4) | 40 (11.0) | 0.309 |
| Hypertension, *n* (%) | 115 (26.6) | 110 (27.9) | 0.660 | 98 (26.8) | 105 (28.8) | 0.563 |
| Pulmonary, *n* (%) | 45 (10.4) | 38 (9.6) | 0.720 | 33 (9.0) | 32 (8.8) | 0.896 |
| Hepatic, *n* (%) | 17 (3.9) | 20 (5.1) | 0.424 | 17 (4.7) | 19 (5.2) | 0.528 |
| Renal, *n* (%) | 3 (0.7) | 4 (1.0) | 0.614 | 3 (0.8) | 4 (1.1) | 0.614 |
| Tumor location | 　 | 　 | 0.892 | 　 | 　 | 0.962 |
| Upper, *n* (%) | 59 (13.6) | 56 (14.2) |  | 55 (15.1) | 54 (14.8) |  |
| Middle, *n* (%) | 88 (20.3) | 84 (21.3) |  | 75 (20.5) | 78 (21.4) |  |
| Lower, *n* (%) | 286 (66.1) | 254 (64.5) |  | 235 (64.4) | 233 (63.8) |  |
| Histologic type | 　 | 　 | 0.651 | 　 | 　 | 0.829 |
| Well, *n* (%) | 42 (9.7) | 31 (7.9) |  | 31 (8.5) | 31 (8.5) |  |
| Moderate, *n* (%) | 101 (23.3) | 94 (23.9) |  | 93 (25.5) | 86 (23.6) |  |
| Poor, *n* (%) | 290 (67.0) | 269 (68.3) |  | 241 (66.0) | 248 (67.9) |  |
| Pathological T stage |  |  | 0.254 |  |  | 0.350 |
| T1, *n* (%) | 56 (12.9) | 42 (10.7) |  | 48 (13.2) | 38 (10.4) |  |
| T2, *n* (%) | 89 (20.6) | 91 (23.1) |  | 72 (19.7) | 82 (22.5) |  |
| T3, *n* (%) | 99 (22.9) | 107 (27.2) |  | 85 (23.3) | 98 (26.8) |  |
| T4, *n* (%) | 189 (43.6) | 154 (39.1) |  | 160 (43.8) | 147 (40.3) |  |
| Pathological N stage |  |  | 0.091 |  |  | 0.417 |
| N0, *n* (%) | 95 (21.9) | 97 (24.6) |  | 86 (23.6) | 91 (24.9) |  |
| N1, *n* (%) | 89 (20.6) | 104 (26.4) |  | 79 (21.6) | 95 (26.0) |  |
| N2, *n* (%) | 92 (21.2) | 70 (17.8) |  | 74 (20.3) | 64 (17.5) |  |
| N3, *n* (%) | 157 (36.3) | 123 (31.2) |  | 126 (34.5) | 115 (31.5) |  |
| pTNM stage |  |  | 0.502 |  |  | 0.819 |
| IA, *n* (%) | 45 (10.4) | 48 (12.2) |  | 40 (11.0) | 46 (12.6) |  |
| IB, *n* (%) | 69 (15.9) | 70 (17.8) |  | 62 (17.0) | 64 (17.5) |  |
| IIA, *n* (%) | 66 (15.2) | 64 (16.2) |  | 56 (15.3) | 62 (17.0) |  |
| IIB, *n* (%) | 72 (16.6) | 63 (16.0) |  | 60 (16.4) | 58 (15.9) |  |
| IIIA, *n* (%) | 47 (10.9) | 52 (13.2) |  | 42 (11.5) | 48 (13.2) |  |
| IIIB, *n* (%) | 66 (15.2) | 51 (12.9) |  | 54 (14.8) | 46 (12.6) |  |
| IIIC, *n* (%) | 68 (15.7) | 46 (11.7) |  | 51 (14.0) | 41 (11.2) |  |
| Operation date | 　 | 　 | 0.049 | 　 | 　 | 0.573 |
| 2012, *n* (%) | 91 (21.0) | 65 (16.5) |  | 71 (19.5) | 60 (16.4) |  |
| 2013, *n* (%) | 98 (22.6) | 78 (19.8) |  | 70 (19.2) | 69 (18.9) |  |
| 2014, *n* (%) | 118 (27.3) | 102 (25.9) |  | 102 (27.9) | 98 (26.8) |  |
| 2015, *n* (%) | 126 (29.1) | 179 (45.4) |  | 122 (33.4) | 138 (37.8) |  |
| Adjuvant chemotherapy, *n* (%) | 282 (65.1) | 261 (66.2) | 0.736 | 233 (63.8) | 245 (67.1) | 0.351 |

ERAS: Enhanced recovery after surgery; SD: Standard deviation; BMI: Body mass index; ASA: American Society of Anesthesiologists; NRS: Nutrition risk screening; pTNM: Pathologic tumor-node-metastasis.

**Table 3 Surgical results for enhanced recovery after surgery and conventional groups**

|  |  |  |  |
| --- | --- | --- | --- |
| **Variable** | **Conventional group (*n* =365)** | **ERAS group (*n* = 365)** | ***P* value** |
| Extent of resection |  |  | 0.716 |
| Proximal gastrectomy, *n* (%) | 9 (2.5) | 6 (1.6) |  |
| Total gastrectomy, *n* (%) | 90 (24.7) | 88 (24.1) |  |
| Distal gastrectomy, *n* (%) | 266 (72.9) | 271 (74.2) |  |
| Reconstruction | 　 | 　 | 0.520 |
| Esophagogastrostomy, *n* (%) | 7 (1.9) | 6 (1.6) |  |
| Billroth-I, *n* (%) | 11 (3.0) | 7 (1.9) |  |
| Billroth-II, *n* (%) | 21 (5.8) | 29 (7.9) |  |
| Roux-en-Y, *n* (%) | 326 (89.3) | 323 (88.5) |  |
| Retrieved LN number (mean ± SD) | 33.02 ± 13.14 | 32.72 ± 14.05 | 0.763 |
| Operation time, min (mean ± SD) | 198.35 ± 40.07 | 195.26 ± 42.94 | 0.315 |
| Estimated blood loss, mL (mean ± SD) | 72.49 ± 34.24 | 69.91 ± 34.22 | 0.308 |
| Intraoperative transfusion, *n* (%) | 23 (6.3) | 16 (4.4) | 0.249 |
| Length of incision, cm (mean ± SD) | 7.58 ± 1.54 | 7.47 ± 1.39 | 0.315 |
| Time to first flatus, d (mean ± SD) | 3.40 ± 1.21 | 2.50 ± 0.81 | < 0.001 |
| Time to first liquid intake, d (mean ± SD) | 3.64 ± 1.20 | 1.02 ± 0.57 | < 0.001 |
| Time to ambulation, d (mean ± SD) | 2.99 ± 1.51 | 1.47 ± 062 | < 0.001 |
| Postoperative hospital stay, d (mean ± SD) | 8.67 ± 2.38 | 7.09 ± 1.76 | < 0.001 |
| 30-d reoperation, *n* (%) | 7 (1.9) | 5 (1.4) | 0.560 |
| 30-d readmission, *n* (%) | 17 (4.7) | 15 (4.1) | 0.717 |
| Medical cost, $ (mean ± SD) | 7814.16 ± 1024.19 | 7621.75 ± 949.73 | 0.009 |

ERAS: Enhanced recovery after surgery; SD: Standard deviation; LN: Lymph node.

**Table 4 Postoperative morbidity and mortality**

|  |  |  |  |
| --- | --- | --- | --- |
| **Variable** | **Conventional group (*n* = 365)** | **ERAS group (*n* = 365)** | ***P* value** |
| Intraoperative complications, *n* (%) | 15 (4.1) | 16 (4.4) | 0.854 |
| Postoperative complications, *n* (%) | 66 (18.1) | 45 (12.3) | 0.030 |
| Wound infection, *n* (%) | 7 (1.9) | 4 (1.1) | 0.546 |
| Pulmonary, *n* (%) | 20 (5.5) | 13 (3.6) | 0.212 |
| Gastroparesis, *n* (%) | 6 (1.6) | 6 (1.6) | 1.000 |
| Anastomotic leakage, *n* (%) | 9 (2.5) | 7 (1.9) | 0.613 |
| Lymphatic leakage, *n* (%) | 4 (1.1) | 2 (0.5) | 0.686 |
| Pancreatic fistula, *n* (%)  | 2 (0.5) | 1 (0.3) | 1.000 |
| Intra-abdominal bleeding, *n* (%)  | 2 (0.5) | 0 (0) | 0.499 |
| Intraluminal bleeding, *n* (%) | 5 (1.4) | 5 (1.4) | 1.000 |
| Intra-abdominal abscess, *n* (%) | 2 (0.5) | 1 (0.3) | 1.000 |
| Deep vein thrombosis, *n* (%) | 2 (0.5) | 0 (0) | 0.499 |
| Ileus, *n* (%)  | 3 (0.8) | 2 (0.5) | 1.000 |
| Cerebrovascular, *n* (%)  | 0 (0) | 0 (0) | 1.000 |
| Cardiac, *n* (%)  | 2 (0.5) | 1 (0.3) | 1.000 |
| Cholecystitis, *n* (%)  | 0 (0) | 1 (0.3) | 1.000 |
| Hepatic, *n* (%)  | 1 (0.3) | 1 (0.3) | 1.000 |
| Renal, *n* (%)  | 1 (0.3) | 1 (0.3) | 1.000 |
| Mortality, *n* (%) | 0 (0) | 0 (0) | 1.000 |
| Clavien-Dindo classification |  |  |  |
| I, *n* (%) | 6 (1.6) | 4 (1.1) | 0.752 |
| II, *n* (%) | 50 (13.7) | 35 (9.6) | 0.083 |
| IIIa, *n* (%) | 4 (1.1) | 4 (1.1) | 1.000 |
| IIIb, *n* (%) | 3 (0.8) | 1 (0.3) | 0.624 |
| IV, *n* (%) | 3 (0.8) | 1 (0.3) | 0.624 |

ERAS: Enhanced recovery after surgery.